PT2385

For research use only.

Catalog No.S8352

PT2385 Chemical Structure

CAS No. 1672665-49-4

PT2385 is a HIF-2α antagonist with luciferase EC50 of 27 nM and no significant off-target activity.

Purity & Quality Control

Choose Selective HIF Inhibitors

Biological Activity

Description PT2385 is a HIF-2α antagonist with luciferase EC50 of 27 nM and no significant off-target activity.
Targets
HIF-2α [1]
(Cell-free assay)
27 nM(EC50)
In vitro

PT2385 blocks HIF-2α dimerization with the HIF1α/2α transcriptional dimerization partner ARNT/HIF1β. PT2385 inhibits the expression of HIF2α-dependent genes, including VEGF-A, PAI-1, and cyclin D1 in ccRCC cell lines and tumor xenografts. PT2385 has no effect on the proliferation or viability of 786-O and A498 cells in culture at concentration as high as 10 μmol/L. Treatment of 786-O cells with PT2385 significantly reduces the levels of mRNA for CCND1, VEGF-A, GLUT1, and PAI-1 in a concentration-dependent manner. Treatment of Hep3B cells with PT2385 reduces hypoxia-induced expression of erythropoietin (EPO) and PAI-1, both known HIF2α target genes[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
786-O NUi3WZFGTnWwY4Tpc44h[XO|YYm= MoDqNlQhcHK| NWO5d3VYSW62YXfvcol{fCCjY4Tpeol1gSCjdDDITWYuOmGucHjhJIlvKGi3bXHuJFc5Pi2RIHPlcIx{KGOxLXX4dJJme3OrbnegTGlHKHKnc4DvcpNqfmViZXzlcYVvfCCjZoTldkAzPCCqcoOgZpkhV06HLVfsc{BtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkCyO{DPxE1w MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ6OUexOkc,OzB{OEm3NVY9N2F-
786-O M3fGWmZ2dmO2aX;uJIF{e2G7 NUTzZ25pOjRiaILz MmfoRY51[WexbnnzeEBi[3Srdnn0fUBifCCKSV[tNoFteGijIHnuJIh2dWGwIEe4Ok1QKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDWSWdHSSClb37j[Y51emG2aX;uJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSxiRVO1NEA:KDBwMESxJO69VS5? M1q4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMki5O|E3Lz5|MEK4PVcyPjxxYU6=
786-O NWi1bHpbTnWwY4Tpc44h[XO|YYm= NVziUWEyOjRiaILz NEnhOZpCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFjJSk0z[WyyaHGgbY4hcHWvYX6gO|g3NU9iY3XscJMh[XO|ZYPz[YQh[XNiZoLl[UBxdGG|bXGgZYRrfXO2ZXSgSWM2OCCob4KgdoVlfWO2aX;uJIlvKF[HR1\BJINwdmOnboTyZZRqd25iYX\0[ZIhOjRiaILzJIJ6KEWOSWPBMEBGSzVyIE2gNE4yPThizszNMi=> NV:xNmRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPFk4OTZpPkOwNlg6PzF4PD;hQi=>
786-O MkXLSpVv[3Srb36gZZN{[Xl? NEnPfIwyOCCvZz;r[y=> Ml2wN{Bl[Xm| NG\nNlZKdiC4aY\vJIlvcGmkaYTpc44hd2ZiSFnGMVJidHCqYTDpckBUS0mGL1Lp[YdmKG2xdYPlJJhmdm:pcnHmeIVlKHerdHigbJVu[W5iN{i2MW8h[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFPDUmQyKG2UTlGgcIV3\Wy|IHH0JFExKG2pL3vnMEBxdyCkaXSg[o9zKDNiZHH5d{BidmRibXXhd5Vz\WRiYX\0[ZIhOTJiaILzJJBwe3RibHHzeEBld3OnIHL5JJFTXC2SQ2KgZY5idHm|aYO= MlW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OEm3NVYoRjNyMki5O|E3RC:jPh?=
786-O MkD1SpVv[3Srb36gZZN{[Xl? NFLtWXoyOCCvZz;r[y=> MXmzJIRigXN? M2fuXWlvKH[rdn:gbY5pcWKrdHnvckBw\iCKSV[tNoFteGijIHnuJHNEUURxQnnl[4UhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiB5OE[tU{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iVlXHSmEhdVKQQTDs[ZZmdHNiYYSgNVAhdWdxa3esJJBwKGKrZDDmc5IhOyCmYYnzJIFv\CCvZXHzeZJm\CCjZoTldkAyOiCqcoOgdI9{fCCuYYP0JIRwe2ViYomgdXJVNVCFUjDhcoFtgXOrcx?= NYf4VIQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPFk4OTZpPkOwNlg6PzF4PD;hQi=>
786-O MUnBcpRqfHWvb4KgZZN{[Xl? NEW5SWUyOCCvZz;r[y=> NF7rOXgzOSCmYYnz M1;yfmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEe4Ok1QKGOnbHzzJJhmdm:pcnHmeIVlKGmwIGPDTWQwSmmnZ3WgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JicnXndoV{e2mxbjDheEAyOCCvZz;r[{wheG9iYnnkJIZweiB{MTDkZZl{ NXjDWJRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPFk4OTZpPkOwNlg6PzF4PD;hQi=>
786-O MVzGeY5kfGmxbjDhd5NigQ>? M4f0clExKG2pL3vn M{XaZlMh\GG7cx?= MmTsUYlvcW23bTDkdpVoKGyndnXsJIlvKFOFSVSvRolm\2VibX;1d4UhgGWwb3fyZYZ1\WRid3n0bEBpfW2jbjC3PFYuVyClZXzsd{BifCBzMDDt[{9s\yxicH:gZollKG[xcjCzJIRigXNiYX7kJI1m[XO3cnXkJIFnfGW{IEGyJIhzeyCyb4P0JIxie3RiZH;z[UBjgSCOQz3NV{9OWyCjbnHsfZNqew>? MlfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OEm3NVYoRjNyMki5O|E3RC:jPh?=
786-O NI\pT2FHfW6ldHnvckBie3OjeR?= NYPzXHd2OTBibXevb4c> M1XQO|Mh\GG7cx?= M4HTWGlvKH[rdn:gbY5pcWKrdHnvckBw\iCKSV[tNoFteGijIHnuJHNEUURxQnnl[4UhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiB5OE[tU{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5idIXtc5Ih\GW{aY\l[EBXTUeIQTDwdo91\WmwIHzleoVteyCjdDCxNEBu\y:tZzygdI8h[mmmIH\vdkA{KGSjeYOgZY5lKG2nYYP1doVlKGGodHXyJFEzKGi{czDwc5N1KGyjc4Sg[I9{\SCkeTDFUGlUSQ>? MnLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OEm3NVYoRjNyMki5O|E3RC:jPh?=

... Click to View More Cell Line Experimental Data

In vivo

PT2385 exhibits good mouse oral bioavailability (110%) and low to medium in vivo clearance. In mice administrated via intravenous injection, the t1/2 of PT2385 is 3.3 h. In rat pharmacokinetics studies, the oral bioavailability (F) when dosed at 10 mg/kg is 40% and the t1/2 is 3.3 h. In dogs, the oral bioavailability (F) is 87% and the t1/2 is 11 h[1]. Treatment of tumor-bearing mice with PT2385 causes dramatic tumor regressions (clear cell renal cell carcinomas). PT2385 exhibits no adverse effect on cardiovascular performance[2].

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: 786-O cells
  • Concentrations: 20, 6.67, 2.22, 0.74, 0.25, 0.082, 0.027, 0.009, 0.003, 0.001 μM
  • Incubation Time: 44 h
  • Method:

    About 7500 of 786-O cells in 180 μL of growth medium are seeded into each well of a 96 well plate with white clear bottom on the first day. Four hours later, serial dilutions of 10x compound stocks are made in growth medium from 500x DMSO stocks, and 20 μL of those 10x stocks are added to each well to make final concentrations as follows (μM): 20, 6.67, 2.22, 0.74, 0.25, 0.082, 0.027, 0.009, 0.003, 0.001, and 0. Each concentration has duplicated wells. About 20 hours later, medium is removed by suction and each well is supplied with 180 μL of growth medium. About 20 μl freshly-made 10x compound stocks are added to each well. About 24 hours later, cell culture medium is removed for the determination of VEGFA concentration using an ELISA kit.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: male CD1 mice
  • Dosages: 3 mg/kg (IV) and 10 mg/kg (PO)
  • Administration: IV or PO
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 77 mg/mL (200.86 mM)
Ethanol 5 mg/mL (13.04 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 383.34
Formula

C17H12F3NO4S

CAS No. 1672665-49-4
Storage powder
in solvent
Synonyms N/A
Smiles CS(=O)(=O)C1=C2C(C(CC2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02553356 Completed Drug: PT2385 Healthy Peloton Therapeutics Inc. September 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HIF Signaling Pathway Map

Related HIF Products

Tags: buy PT2385 | PT2385 supplier | purchase PT2385 | PT2385 cost | PT2385 manufacturer | order PT2385 | PT2385 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID